The Food and Drug Administration (FDA) reports the discontinuation of Menest (esterified estrogens; Pfizer) 2.5mg tablets. Pfizer has decided to permanently discontinue this tablet strength.
Menest is indicated for the treatment of:
- Moderate to severe vasomotor symptoms associated with the menopause
- Moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered
- Female hypogonadism
- Female castration
- Primary ovarian failure
- Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease.
- Prostatic carcinoma – palliative therapy of advanced disease
Menest is also available in 0.3mg, 0.625mg, and 1.25mg tablets.
For more information visit Pfizer.com.